The """"""""classical"""""""" DA (DA) hypothesis of schizophrenia proposed that hyperactivity of DA transmission is responsible for the positive symptoms (hallucinations, delusions) observed in this disorder . Several studies have recently demonstrated that amphetamine-induced DA release, measured at the level of the striatum as a whole, was increased in untreated patients with schizophrenia. These findings suggested an abnormal regulation of striatal DA release in schizophrenia. Two important limitations of these previous studies are that these measurements were restricted to the striatum and to the striatum as a whole. The ligands used did not provide enough signal to noise ratio to quantify D2 receptors in extrastriatal and the cameras used did not have the resolution required to differentiate the signals from ventral and dorsal striata. Recent developments in radiochemistry and instrumentation now permit a much more detailed mapping of DA presynaptic function with PET. We recently obtained evidence that the new PET D2 receptor radiotracer, [tSF]fallypride enable reliable measurements of both striatal and extrastriatal D2 receptors, and that its binding is vulnerable to acute fluctuations in endogenous DA. Furthermore, we recently demonstrated that the PET camera ECAT EXACT HR+ provides tile resolution to Study functional subdivisions of the Striatum. In preiiminary data, we made the observation that DA transmission in schizophrenia is not elevated in the ventral striatum, as anticipated, but rather in the precommiissural dorsal caudate nucleus (preDCA), the Striatal region that processes information; flow from the dorso- lateral prefrontal cortex (DLPFC). Here, we propose to further validate the use of [18F]fallypride to detect changes in endogenous DA in striatal and extrastriatal regions in baboons (specific aim 1) and healthy controls (specific aim 2), and study amphetamine-induced DA release in the nigro-striatal system (caudate and putamen), mesolimbic system (ventral striatum,, hippocampus and amygdala) and mesoeortical system (temporal and cingulate cortices). The hypothesis is that amphetamine-induced DA release will be elevated in the preDCA and blunted in mesocorticat DA system in patients with schizophrenia. Results from this Project will inform animals models developed in Projects by Javitt, Kandel, Rayport, and will provide neurobiological insights about schizophrenia that will be important for the development of more focused therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH066171-05
Application #
7643271
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
5
Fiscal Year
2008
Total Cost
$206,067
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Slifstein, Mark; van de Giessen, Elsmarieke; Van Snellenberg, Jared et al. (2015) Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72:316-24
Chuhma, Nao; Mingote, Susana; Moore, Holly et al. (2014) Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 81:901-12
Poels, E M P; Kegeles, L S; Kantrowitz, J T et al. (2014) Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 19:20-9
Poels, Eline M P; Kegeles, Lawrence S; Kantrowitz, Joshua T et al. (2014) Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 152:325-32
Poels, Eline M P; Girgis, Ragy R; Thompson, Judy L et al. (2013) In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology (Berl) 228:167-74
Kisby, Glen E; Moore, Holly; Spencer, Peter S (2013) Animal models of brain maldevelopment induced by cycad plant genotoxins. Birth Defects Res C Embryo Today 99:247-55
Mihali, Andra; Subramani, Shreya; Kaunitz, Genevieve et al. (2012) Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother 12:785-99
Ward, Ryan D; Simpson, Eleanor H; Richards, Vanessa L et al. (2012) Dissociation of hedonic reaction to reward and incentive motivation in an animal model of the negative symptoms of schizophrenia. Neuropsychopharmacology 37:1699-707
Abi-Dargham, Anissa; Xu, Xiaoyan; Thompson, Judy L et al. (2012) Increased prefrontal cortical D? receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112. J Psychopharmacol 26:794-805
Lyon, Gholson J; Abi-Dargham, Anissa; Moore, Holly et al. (2011) Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull 37:108-17

Showing the most recent 10 out of 31 publications